Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $83 | $31 | $35 | $42 |
| Gross Profit | -$83 | -$31 | -$35 | -$42 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,979 | $3,569 | $12,995 | $27,220 |
| G&A Expenses | $3,259 | $3,723 | $4,656 | $5,661 |
| SG&A Expenses | $3,299 | $3,923 | $4,656 | $5,661 |
| Sales & Mktg Exp. | $40 | $200 | $0 | $0 |
| Other Operating Expenses | -$83 | -$14,984 | $0 | $0 |
| Operating Expenses | $6,195 | -$7,492 | $17,651 | $32,881 |
| Operating Income | -$6,278 | $7,492 | -$17,651 | -$32,881 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1,239 | -$14,404 | -$215 | $414 |
| Pre-Tax Income | -$7,517 | -$6,912 | -$17,866 | -$32,467 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,517 | -$6,912 | -$18,571 | -$31,948 |
| % Margin | – | – | – | – |
| EPS | -8.08 | -30.05 | -11.08 | -19.48 |
| % Growth | 73.1% | -171.2% | 43.1% | – |
| EPS Diluted | -8.08 | -29.95 | -11.08 | -19.48 |
| Weighted Avg Shares Out | 931 | 230 | 1,676 | 1,640 |
| Weighted Avg Shares Out Dil | 931 | 231 | 1,676 | 1,640 |
| Supplemental Information | – | – | – | – |
| Interest Income | $503 | $375 | $297 | $562 |
| Interest Expense | $15 | $11 | $215 | $43 |
| Depreciation & Amortization | $83 | $31 | $35 | $42 |
| EBITDA | -$7,419 | -$6,870 | -$17,616 | -$32,839 |
| % Margin | – | – | – | – |